Systematic review of 36 studies (6 RCTs, 30 real-world) in adults with thyroid eye disease: teprotumumab improved proptosis (RCT RR 4.55; 82% real-world) and diplopia (RR 2.13; 60%), but increased hyperglycaemia (RR 2.67) and hearing impairment (RR 4.05).
Meta-analysisn = 36 studies
Sun et al. Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies